DUBLIN & TORONTO--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN) and Transition Therapeutics Inc. (TSX: TTH, NASDAQ:TTHI) today announced the United States Patent and Trademark Office issued US patent number 7,521,481 on April 21, 2009. The patent is entitled “Methods of Preventing, Treating and Diagnosing Disorders of Protein Aggregation,” and generally claims methods for treating Alzheimer’s disease comprising administering scyllo-inositol (ELND005). The patent will expire in the year 2025 or later due to any patent term extensions.
